Longevity Research Limitations and Safety

Why this page exists

Longevity headlines often move from "extended lifespan in mice" to "may help you live longer" in one step. This page explains the gaps between those claims and proof, and the safety questions to ask. Evidence labels: established, promising but limited, preclinical (cells/animals only), insufficient evidence, marketing claim. Education only; it does not recommend products or tell you what to take.

Research limitations

Animal results do not automatically carry over. Rapamycin, for example, extended lifespan in genetically varied mice at three test sites. [1] Whether similar drugs slow aging in people is unproven; a 2025 JAMA review said the health benefits of reducing senescent cells in humans remain unclear. [2] In cancer research, a review found the average rate of successful translation from animal models to clinical trials was under 8%. [3] That figure is from cancer, not aging, so it shows the general problem rather than a measured rate for longevity drugs. Label: preclinical.

Lifespan trials in people are hard. Measuring who lives longer takes decades, so studies use shortcuts. Human trials of calorie restriction measured risk factors and aging clocks, and the authors said a conclusive test needs long follow-up on chronic disease and death. [4]

Surrogate endpoints and biomarkers. A surrogate is a measure used instead of the outcome that matters. Experts say no consensus exists on how to validate aging biomarkers before clinical use. [5] Surveyed experts named six barriers to translating them, including the need for markers that are robust at the level of individuals. [6] A change in a blood marker, DNA methylation score or tracker number is not the same as living longer or staying well. See Biomarkers and Biological Age Tests.

Small, short trials. The PEARL rapamycin trial lasted 48 weeks, and its main outcome (visceral fat) did not change significantly. [7] A review of NAD+ precursors said small sample sizes limit interpretation. [8]

Observational studies. Large cohort studies on activity found strong links to lower risk, but they show association; the pooled data are observational. [9]

Longevity clinic and product claims

We looked for systematic reviews testing the health outcomes of longevity clinic packages (testing panels plus supplements or prescriptions) and found none that we could read. Proper evidence not found. Treat such claims as marketing claims until supported by trials in people. A 2024 review of anti-aging medicines described them as agents in ongoing trials. [10]

Safety

• Supplements are not risk-free. In a meta-analysis of 68 trials, antioxidant supplements did not reduce death overall, and beta carotene, vitamin A and vitamin E may increase mortality in lower-bias trials. [11]
• Prescription drugs have real risks. MedlinePlus warns that sirolimus can lower resistance to infection and may raise cancer risk, and that metformin can cause lactic acidosis. [12][13] See Experimental Longevity Compounds.
• Tests have limits. The FDA says wellness-type direct-to-consumer tests are generally not reviewed before sale and have varying levels of supporting evidence. [14]
• Check with a professional. Pregnancy, medicines, kidney or liver disease and older age all change risk: see older adults, medication interactions and talking with a health professional.

A checklist for claims

1. Was it tested in people, or only in cells or animals?
2. Did it measure health outcomes or only a lab number?
3. How many people, for how long, and was there a placebo group?
4. Who pays for the claim, and is there something to sell?
5. What are the risks, and who should not use it?

For what does have human support, see Longevity Interventions: What Human Evidence Exists and How We Label Evidence.